Is Retatrutide Safe for Women? Trial Data

Retatrutide is an investigational triple receptor agonist being studied for obesity and type 2 diabetes, with no marketing authorisation in the UK or elsewhere. Questions about whether retatrutide is safe for women are understandable given the interest in this medicine, but its safety profile, including any effects specific to women, is still being established through ongoing clinical trials. This article summarises what trial data have reported, outlines the known side effects, and explains the particular safety considerations relevant to women, including those of childbearing potential. Retatrutide is not available outside an authorised clinical trial.

What is retatrutide and what is its current status in the UK?

Retatrutide is an investigational triple receptor agonist with no UK marketing authorisation; it can only be accessed within an authorised clinical trial and is not available through NHS or private prescribing.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be accessed only within an authorised clinical trial.^[2][1] It is an investigational medicine being studied for the management of obesity and type 2 diabetes. Unlike licensed treatments such as tirzepatide (Mounjaro) or semaglutide (Wegovy), retatrutide is not available through NHS or private prescribing outside a formal research setting.

Retatrutide is a triple receptor agonist, acting on glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors simultaneously. This triple mechanism distinguishes it pharmacologically from currently authorised dual or single agonists, though no head-to-head trials with licensed medicines have been completed and published in peer-reviewed form to date, and no direct comparisons can be drawn from existing data.

Because retatrutide has no UK marketing authorisation, it cannot be advertised (MHRA guidance on promoting unlicensed medicines applies).^[1] Any product sold online under this name is not a licensed medicine and may be falsified or unsafe. People interested in weight management options that are currently available can discuss licensed treatments with their GP. Women interested in participating in a retatrutide clinical trial can search for authorised UK studies via the NIHR Be Part of Research service.^[20] No UK launch date for retatrutide has been announced, and no timeline can be given.

What have clinical trials reported about retatrutide in women?

Phase 2 and Phase 3 trial data have not been stratified by sex in primary analyses, so clinically meaningful sex-specific differences in efficacy or safety have not yet been established.

Clinical trial findings on retatrutide have been reported from the Phase 2 programme published in the New England Journal of Medicine, and the Phase 3 TRIUMPH and TRANSCEND programmes have since reported further data.^[4] These trials enrolled adults with obesity or overweight, with or without type 2 diabetes, and included both men and women. Published results have generally not been stratified by sex in the primary analyses available to date, and clinically meaningful sex-specific differences in efficacy or safety have not been established from the data published so far.

In the Phase 2 trial, participants receiving retatrutide at higher doses experienced substantial reductions in body weight over the trial period. These findings were reported in a defined trial population, under controlled conditions, and cannot be generalised as outcomes an individual would expect. The trial populations excluded people who were pregnant, breastfeeding or planning pregnancy, which is an important limitation when considering the relevance of these findings to women of childbearing potential.

Phase 3 data have been reported primarily through company communications; peer-reviewed publications of the TRANSCEND and TRIUMPH programmes should be consulted when available, as they will provide a more complete and independently verified evidence base. Trial findings represent average outcomes across a study group and are subject to the limitations of trial design, including duration, population selection and follow-up. Larger and longer studies are needed before the full benefit and risk profile in any subgroup, including women, can be characterised with confidence. Retatrutide remains an investigational medicine, and its efficacy and safety profile are still being established through ongoing research.

What side effects have been seen in women taking retatrutide in trials?

The most commonly reported side effects in retatrutide trials are nausea, vomiting, diarrhoea and constipation; the complete adverse effect profile, including any women-specific effects, remains under investigation.

The side effects reported in retatrutide trials have broadly reflected those seen with other medicines that act on GLP-1 receptors, though retatrutide's triple agonist mechanism means its full safety profile is still being characterised and findings should be attributed to trial data rather than assumed from class effects alone. The most commonly reported adverse effects in trial participants included nausea, vomiting, diarrhoea and constipation.^[3][4]

Acute pancreatitis has been reported in association with GLP-1 receptor agonist class medicines, including post-marketing reports of necrotising pancreatitis and reports with fatal outcomes.^[6] Whether retatrutide carries a comparable risk has not been fully established from trial data alone. If a trial participant experiences persistent severe abdominal pain, with or without vomiting, they should contact the trial team immediately and seek urgent medical attention. They should not wait to see whether symptoms resolve.

Gallbladder and biliary events, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), have been reported with GLP-1-based therapies.^[7][8] Whether retatrutide carries a similar risk is under investigation and has not been fully characterised from available trial data.

Injection site reactions, decreased appetite and fatigue have also been noted in trial reports. Because retatrutide is investigational, its complete adverse effect profile, including any effects that may be more relevant to women specifically, such as interactions with hormonal physiology, has not been fully characterised. Participants in trials who experience adverse effects should report them to the trial team under the study protocol. Suspected side effects of any medicine can also be reported to the MHRA via the Yellow Card scheme at yellowcard.^[18][19]mhra.gov.uk. Anyone who believes they have been sold retatrutide outside a clinical trial should contact their GP and report the product to the MHRA.

Are there specific safety concerns for women, including pregnancy?

Women who are pregnant, breastfeeding or planning pregnancy are excluded from retatrutide trials because no safety data exist in these groups; women enrolled must follow the trial protocol's contraception requirements.

There are several specific safety considerations relevant to women in the context of retatrutide trials, and the most significant is that women who are pregnant, breastfeeding or planning a pregnancy are excluded from participation. This exclusion reflects the absence of safety data in these groups and is standard practice for investigational medicines. Because no data exist on the effects of retatrutide in pregnancy or during breastfeeding, its safety in these circumstances is entirely unknown. Women enrolled in a retatrutide trial should follow the contraception requirements set out in the trial protocol, as these are determined by the trial team based on the specific study design.

For context, the UK SmPC for tirzepatide (Mounjaro) specifically advises that women of childbearing potential should use an additional non-oral contraceptive method for four weeks after starting treatment and for four weeks after each dose increase, because tirzepatide can slow gastric emptying and may reduce the absorption of oral contraceptives taken during that period.^[11][12] This recommendation is specific to tirzepatide and is based on its UK SmPC; it should not be assumed to apply to retatrutide or to GLP-1-based medicines as a class. Women in a retatrutide trial should ask the trial team what contraceptive requirements apply to them under the study protocol.

Women with pre-existing diabetic eye disease should also be aware that rapid improvements in blood glucose control have been associated with transient worsening of pre-existing pre-proliferative or proliferative diabetic retinopathy in trials of medicines in this class.^[15][16] This is a consideration that would apply to women with type 2 diabetes enrolled in retatrutide trials, and appropriate ophthalmic monitoring should be discussed with the trial team.

Women participating in a retatrutide trial are advised to carry their trial documentation and to inform any healthcare professional they see in an emergency or unscheduled care setting that they are enrolled in a clinical trial, sharing the trial contact details where possible. Any woman considering participation in a retatrutide clinical trial should discuss her full medical history, contraceptive use and reproductive plans with the trial team before enrolment.

Frequently Asked Questions